Ablation of the Epicardial Substrate in the Right Ventricular Outflow Tract in a Patient With Brugada Syndrome Refusing Implantable Cardioverter Defibrillator Therapy

Szeplaki G., Oezcan E. E., Osztheimer I., Tahin T., Merkely B., Geller L.

CANADIAN JOURNAL OF CARDIOLOGY, vol.30, no.10, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 30 Issue: 10
  • Publication Date: 2014
  • Doi Number: 10.1016/j.cjca.2014.05.019
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Dokuz Eylül University Affiliated: No


Brugada syndrome is associated with a high risk of sudden cardiac death. Currently, the cornerstone of therapy is implantation of an implantable cardioverter defibrillator (ICD). Recently, a novel approach to preventively ablate the substrate located in the anterior epicardial region of the right ventricular outflow tract showed promising results by reducing the number of ventricular fibrillation episodes in patients with ICD. Here we report on a patient with Brugada syndrome who refused ICD therapy in whom a successful epicardial right ventricular outflow tract substrate ablation was performed. In some special cases, ablation therapy might be considered as the sole therapeutic option for these patients.